Overview

* Vanda Q3 total net product sales rise 18% yr/yr, driven by Fanapt growth

* Company reports Q3 net loss of $22.6 mln, up from $5.3 mln last year

* Vanda advancing pipeline with multiple FDA reviews and submissions expected

Outlook

* Vanda revises 2025 revenue guidance to $210-$230 mln from $210-$250 mln

* Company expects year-end 2025 cash between $260 mln and $290 mln

* Bysanti NDA for bipolar I disorder under FDA review, action date Feb 21, 2026

Result Drivers

* FANAPT SALES - Fanapt sales increased by 31% in Q3 2025, driven by a 35% increase in prescriptions

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.38

Q3 Net -$22.58

Income mln

Q3 Basic -$0.38

EPS

Q3 $87.54

Operatin mln

g

Expenses

Q3 -$31.28

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Vanda Pharmaceuticals Inc ( VNDA ) is $13.00, about 57.1% above its October 28 closing price of $5.58

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)